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raditional measures of disease burden,such as
prevalence and mortality, have vastly underestimated
the personal, societal, and economic burdens of mental
illnesses,which are more often disabling than lethal.The
highly regarded World Health Organization (WHO)–
World Bank study of the Global Burden of Disease
1
defines the “disability-adjusted life year” (DALY) as
healthy years of life lost to (i) premature death, or (ii)
disability.As a cause of DALYs,depression ranks second
only to heart disease in established market economies,
and fourth overall.
2 Realization of the need for treat-
ments and, ultimately, for tested approaches to preven-
tion has grown in response to the recognition of this high
degree of burden.
Approaches to drug discovery
The textbook approach to drug discovery moves in logi-
cal order from the bench to the bedside to the clinic to
the community in sequentially ordered steps:molecular
targets are defined through basic research;biochemical
assays are used to screen for lead compounds; animal
studies establish pharmacokinetic and pharmacodynamic
parameters;and toxicology studies assess safety and risk.
All these lead to human clinical trials in a multiphased
developmental process that has been well documented.
Though widely held as the ideal for basic,translational,
and clinical research,the textbook approach has not char-
acterized drug development in mental health. Rather,
there have been three major discovery paradigms.
3
Serendipity,the completely fortuitous discovery of ther-
apeutic effects,is the typical pattern for drug discovery.
In the early 1950s,for example,chlorpromazine was syn-
thesized by Charpentier at Rhone-Poulenc.The surgeon
Henri Laborit used the compound to induce a state of
“artificial hibernation”and in 1952 forecast its potential
for use in psychiatry. In that year, benefits were identi-
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T
Mental disorders are among the most disabling of all dis-
eases. Effective well-documented medications have been
available for many decades. Yet, limited understanding of
the pathophysiology of mental disorders has impeded the
development of novel treatments. Drug discovery must
move toward a new mechanism-based paradigm using
the tools of contemporary genetic and molecular medi-
cine. At the same time, this new paradigm must be
matched by an equivalent effort to modernize established
approaches to clinical trials methodology.
Dialogues Clin Neurosci. 2002;4:325-328.fied in single cases and as monotherapy in open case
series of patients diagnosed with bipolar illness and psy-
chosis. Study of the drug expanded to other countries
and the first controlled trial was carried out in England
and published in 1954.
The discovery of imipramine followed roughly the same
sort of path. The drug was developed by Geigy in
Switzerland in the 1940s as a possible antihistamine.No
particular advantage was observed and the drug was
“shelved.” It was tried in schizophrenia in 1955 and
failed, though in retrospective analysis, certain mood-
elevating effects were observed. It was then pursued in
depression and issued in the late 1950s,but not without
significant difficulty in acceptance both within the com-
pany and the community.
A related approach to drug development is represented
by the well-known phenomenon of compounds in search
of a disease.That is, drugs with suspected central ner-
vous system (CNS) activity are studied in various clini-
cal populations until a therapeutic signal is detected.The
late 1950s experiences of Nathan Kline and others with
the application of antituberculosis drugs in the mood
and anxiety disorders are illustrative of this approach to
drug development.
Once a successful drug is developed, compounds with
similar structures and activities (so-called “me-too”com-
pounds) are tested for the purpose of identifying specific
comparative advantages.
Gaps in the discovery process
Though the serendipitous, nonlinear approach to drug
development has produced a number of important and
even revolutionary changes in our approaches to the care
of people with mental illnesses, there are very serious
gaps in our treatment armamentarium.
Heart disease,the most disabling of illnesses,has at least
15 distinct classes of drugs available for use in treatment,
most having been developed in the last decades. In
depression,we have only a handful based on monoamine-
elevating mechanisms of monoamine oxidase inhibition,
serotonin,or norepinephrine uptake inhibitors.In schiz-
ophrenia,there are even fewer approaches characterized
as dopamine receptor antagonists or some mixture of
other actions (atypicals). In bipolar disorder, we have
three:lithium,anticonvulsants,and atypical antipsychotics.
The number of distinct classes of treatment for mental
disorders has not increased appreciably since the 1950s.
Clearly,we are dealing with a very complex system,and
the complexity seems to be increasing as our knowledge
increases. The order of complexity in the CNS goes
from 10
2 (the number of neurotransmitters) to 10
12 (the
number of synapses). In addition, data from imaging
and from neuropsychology show that the pathology of
mental disorders is widely distributed through the CNS.
Genetic studies have shown that these diseases are
polygenetic with multiple biochemical pathways that
may contribute to the expression of a single disease.
Environmental factors may contribute to as much 
as half the variance in disease expression.Coupled with
a system of diagnostic classification that is often
ambiguous and incomplete,our challenge is formidable
indeed.
New opportunities
More than ever before we now have the opportunity to
revolutionize drug discovery for the mental illnesses.
With discoveries in molecular biology, genomics, pro-
teomics, bioinformatics, and automation, we have the
tools we need to move to a whole new approach to drug
discovery.
4-6 Experiments or procedures that took years
now take hours as information produced through robot
technology and combinatorial chemistry is fed to super-
computers for processing and comparison to established
informatics resources.
7 Laboratories in the private sec-
tor
8 and the public sector have revolutionized their
methodologies to search for promising compounds.
Using genomics and proteomics, it will be possible to
produce mechanism-based classifications of clinical
patient populations and disease targets for therapeutic
or prophylactic intervention for these new compounds.
All this will move us from an approach based on
serendipity to one based on rationality.
9
The therapeutics of the future will be expected to iden-
tify specific molecular targets with minimal side effects
in genetically defined clinical populations.
10 Our current
approaches are largely still broad targets with high side
effect burdens in ill-defined patient populations.
An increasingly important piece of this puzzle will be
the growing importance of biomarkers and surrogate
markers using brain imaging and other technologies for
lead compound identification and optimization, and
proof of principle.
11 Some very promising approaches
have begun to appear in the literature,
12,13 particularly in
the area of Alzheimer disease.
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Like the drugs we use, the methods we use to study
them in human clinical trials were established for the
most part in the 1940s and 1950s with the first modern
randomized controlled trial, the Medical Research
Council (MRC) trial of streptomycin.
Yet nearly everything we do in clinical trials in depres-
sion minimizes treatment response, enhances placebo
response, and, in the case of combination treatment
approaches, inflates the value of active psychosocial
comparators.There are many factors that contribute to
this.
Patient selection
Subject selection often is limited by censoring the sever-
ity distribution through entry criteria where exclusions
often require elimination of patients who are suicidal or
psychotic, or have a variety of common comorbidities,
such as physical illness, substance abuse, or personality
disorder.Since these are typically associated with sever-
ity,elimination leads to preferential recruitment of less
severely ill subjects. Similarly, many studies have long
no-treatment periods for observation and diagnostic
purposes.Clinicians are not likely to withhold treatment
from severely ill patients in whom immediate treatment
is seen as an absolute necessity.Thus,only those patients
who can tolerate a long no-treatment period are
recruited.These patients are likely to be less severely ill.
It has long been observed that severity and placebo
response are inversely related.
If advertising is used as the primary source of recruit-
ment,a group of high-likelihood placebo responders,the
“worried well,” are often the ones recruited. If, on the
other hand,the recruitment is largely from active clinic
or practice populations,there is likely to be preferential
treatment of nonresponders under the justification that
it is inappropriate to “rock the boat” for patients that
are doing well by switching to a new treatment.
Study operations
In large,multiple-site studies,recruitment is often set as
a horse-race with enrollment concluded when the over-
all study sample is achieved. Payment to sites is largely
on a per-patient basis.Therefore, as the study recruit-
ment goal appears closer, there is a financial incentive
to enroll subjects while enrollment is still possible.Over
time,that could lead to a drift in criteria:mild symptoms
are seen as more serious, and borderline eligibility gets
to be considered acceptable. This erosion of severity
promotes placebo responder recruitment.
In combination treatment studies,operational concerns
minimize differences between pharmacological and psy-
chosocial treatments.Typically, the approach to phar-
macotherapy is rigid with fixed dosing and short dura-
tion—an approach uncharacteristic of clinical practice.
Clinicians in the pharmacotherapy arm must behave
robotically and in a manner unlike the way they gener-
ally work.Training and supervision are minimal.Those
doing the psychosocial treatment,on the other hand,are
typically highly selected, well-paid, well-trained, and
closely supervised.We therefore commonly encounter
trials in which expertly done psychotherapy beats poorly
done pharmacotherapy,and cannot separate the opera-
tional aspects from the true clinical effect of the differ-
ent treatment approaches.
Outcome measures
In psychiatry trials in general, and in depression trials
in particular,there is a tradition of using too many mea-
sures, most of which are rating scales or self-report
forms of dubious validity and notorious unreliability.
Measures are selected because they have worked in the
past, and are therefore uninformed by contemporary
science and knowledge of etiology or pathophysiology.
There are few examples of composite,event-based mea-
sures,such as are typically used in cardiovascular trials
(major adverse cardiac events, MACE), in mental
health.We need to have more.Treatments may be hav-
ing effects that our measures are incapable of captur-
ing.
Analysis
The preferred approaches to statistical analysis of trials
data, such as “intent to treat” or “last observation car-
ried forward,” may reward placebo response. Newer
approaches such as mixed-effects modeling and survival
models may provide crisper alternatives for the identi-
fication of treatment effects.And,of course,statisticians
continually remind us that effect size estimation,not sta-
tistical significance,should be the criterion applied to all
trials.
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Clinical trials often fail because we feel constrained to
follow the classic approaches to clinical trials method-
ology. New science and new treatments should be sub-
jected to a methodology that is appropriate and built
upon the best of our current knowledge.There is a press-
ing need to reengineer the standard approaches to clin-
ical trials in the mental disorders.
We also need to remember that discovery and develop-
ment are the beginning and midpoint of treatment
development,not the end.Traditional models have lim-
ited generalizability, restricted outcome measures, and
leave substantial amounts of nonresponse, residual
symptomatology, and associated disability.
14 New prag-
matic trials,based on approaches articulated by Peto and
colleagues,
15 are expanding our vision with respect to
treatment assessment in our field.
Finally,we need to remember that mental disorders are
complex, chronic, and often recurring. Medications are
important and necessary,but they do not constitute the
total approach to long-term care necessary for people
with these serious conditions.In the US and elsewhere,
we learned a sad lesson and incurred great suffering in
the rush to “deinstitutionalize” people hospitalized for
care of mental illnesses, but provided with little post-
hospital care beyond drugs.As recently articulated in the
UK
16 with respect to schizophrenia:“… The manage-
ment of schizophrenia involves a comprehensive pack-
age of care,[…] drug therapy currently accounts for less
than 5% of the total health care costs for schizophre-
nia.” ❏
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El descubrimiento de fármacos y la 
enfermedad mental
Los trastornos mentales están entre las más incapaci-
tantes de todas las enfermedades. Durante muchas
décadas se ha dispuesto de medicamentos efectivos,
bien documentados. Sin embargo la comprensión limi-
tada de la fisiopatología de los trastornos mentales ha
impedido el desarrollo de nuevos tratamientos. El des-
cubrimiento de fármacos debe trasladarse hacia un
nuevo paradigma basado en el mecanismo que utilice
las herramientas de la genética y la medicina molecu-
lar contemporáneas. Al mismo tiempo, este nuevo
paradigma debe acompañarse de un esfuerzo equiva-
lente para modernizar las aproximaciones que se han
establecido para la metodología de los ensayos clínicos.
Découvertes médicamenteuses et maladies
mentales
Les troubles mentaux font partie des maladies les plus
handicapantes. Bien que des médicaments dont l’effi-
cacité a été prouvée soient disponibles depuis des
dizaines d’années, le développement de nouveaux
traitements a été gêné par la compréhension limitée
de la physiopathologie des troubles mentaux. La
découverte médicamenteuse doit s’orienter vers un
nouveau modèle basé sur les mécanismes qui utilise les
outils contemporains de la génétique et de la méde-
cine moléculaire. En même temps, ce nouveau modèle
doit être assorti d’un effort équivalent pour moderni-
ser les approches existantes de la méthodologie des
études cliniques.